Covid-19 vaccines—immunity, variants, boosters
DH Barouch - New England Journal of Medicine, 2022 - Mass Medical Soc
Covid-19 Vaccines — Immunity, Variants, Boosters | New England Journal of Medicine Skip to
main content The New England Journal of Medicine homepage Advanced Search SEARCH …
main content The New England Journal of Medicine homepage Advanced Search SEARCH …
Adenoviral vector-based vaccine platform for COVID-19: Current status
The coronavirus disease (COVID-19) breakout had an unimaginable worldwide effect in the
21st century, claiming millions of lives and putting a huge burden on the global economy …
21st century, claiming millions of lives and putting a huge burden on the global economy …
Guidelines on the Use of therapeutic apheresis in clinical practice–Evidence‐Based approach from the Writing Committee of the American Society for Apheresis: The …
L Connelly‐Smith, CR Alquist, NA Aqui… - Journal of clinical …, 2023 - Wiley Online Library
Abstract The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …
[HTML][HTML] Use of the Janssen (Johnson & Johnson) COVID-19 vaccine: updated interim recommendations from the advisory committee on immunization practices …
SE Oliver - MMWR. Morbidity and mortality weekly report, 2022 - cdc.gov
On December 16, 2021, after reviewing updated vaccine effectiveness and safety data, the
Advisory Committee on Immunization Practices made a preferential recommendation for the …
Advisory Committee on Immunization Practices made a preferential recommendation for the …
Retinal vascular occlusions in COVID-19 infection and vaccination: a literature review
S Yeo, H Kim, J Lee, J Yi, YR Chung - Graefe's Archive for Clinical and …, 2023 - Springer
Purpose Abnormal hypercoagulability and increased thromboembolic risk are common in
patients with coronavirus disease (COVID-19). COVID-19 has been suggested to cause …
patients with coronavirus disease (COVID-19). COVID-19 has been suggested to cause …
Pathogenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT)
Vaccine-induced immune thrombotic thrombocytopenia (VITT; synonym, thrombosis with
thrombocytopenia syndrome, is associated with high-titer immunoglobulin G antibodies …
thrombocytopenia syndrome, is associated with high-titer immunoglobulin G antibodies …
Vaccine-induced immune thrombotic thrombocytopenia
DB Cines, A Greinacher - Blood, 2023 - ashpublications.org
Within the first months of the COVID-19 vaccination campaign, previously healthy recipients
who developed severe thrombosis (often cerebral and/or splanchnic vasculature) and …
who developed severe thrombosis (often cerebral and/or splanchnic vasculature) and …
Monoclonal and oligoclonal anti-platelet factor 4 antibodies mediate VITT
AJ Kanack, A Bayas, G George… - Blood, The Journal …, 2022 - ashpublications.org
Kanack and colleagues analyze anti-platelet factor 4 antibodies from 5 patients with vaccine-
induced thrombotic thrombocytopenia (VITT) secondary to COVID-19 adenoviral vaccination …
induced thrombotic thrombocytopenia (VITT) secondary to COVID-19 adenoviral vaccination …
[HTML][HTML] Platelet-activating anti-PF4 disorders: an overview
TE Warkentin - Seminars in hematology, 2022 - Elsevier
Abstract Platelet factor 4 (PF4) is a highly cationic tetrameric protein that can be targeted by
platelet-activating anti-PF4 antibodies of immunoglobulin G (IgG) class. Certain features of …
platelet-activating anti-PF4 antibodies of immunoglobulin G (IgG) class. Certain features of …